相关实验视频

Updated: Jan 16, 2026

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Published on: December 30, 2025

在糖尿病相关的勃起功能障碍中,通过microRNAs调节内甲蛋白受体表达

Haibo Li¹, Jinwei You², Jiao Cang³

¹Department of Urology, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, Nanjing, China.

Biochemical pharmacology

|October 5, 2025

概括

下调的microRNAs (miRNAs) 在2型糖尿病勃起功能障碍 (T2DMED) 中增加内甲蛋白受体A型 (ETA). 恢复miR-30-5p水平改善了T2DMED大鼠的勃起功能,这表明了一个新的治疗点.

科学领域:

内分泌学在内分泌学.
分子生物学分子生物学
泌尿器科泌尿器科泌尿器科泌尿器科

背景情况:

勃起功能障碍 (ED) 是2型糖尿病 (T2DM) 的常见并发症.
末端素受体A型 (ETA) 在T2DM相关ED的发病过程中起着关键作用.
微RNAs (miRNAs) 涉及ED病理生理学,并代表潜在的治疗点.

研究的目的:

调查失调的miRNAs在调节T2DM相关ED中的内啡素受体A型基因 (EDNRA) 中的作用.
识别针对EDNRA的特定miRNA并评估它们在T2DMED中的表达.
评估在T2DMED中恢复miRNA水平的治疗潜力.

主要方法:

针对EDNRA的miRNAs的AI辅助预测.
用RNA芯片分析和定量聚合酶连锁反应 (qPCR) 来分析小鼠体洞穴体 (CC) 中的miRNA表达.
露西法酶试验证实了miRNA-EDNRA相互作用以及miR-30-5p的体内静脉病毒输送.

主要成果:

在T2DMED大鼠的CC中,ETA水平显著升高.
在T2DMED大鼠中,miR-30-5p,miR-96-5p和miR-27a-3p的下调显著.
在体外,低氧抑制了miRNA的表达,增加了ETA的表达. 在体内,miR-30-5p的输送降低了T2DMED大鼠的ETA水平,并恢复了勃起功能.

结论:

下调的miRNAs通过上调ETA表达来促进T2DMED.
准EDNRA调节的miRNAs为T2DMED提供了一个新的治疗策略.
恢复特定的miRNAs显示出治疗T2DMED的前景.

关键词:

糖尿病是一种糖尿病.末端蛋白受体A型的受体勃起功能障碍勃起功能障碍是什么治疗疗法治疗疗法这是一个微型RNA.

更多相关视频

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...